Relatlimab
- Generic Name
- Relatlimab
- Brand Names
- Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1673516-98-7
- Unique Ingredient Identifier
- AF75XOF6W3
- Background
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint inhibit...
- Indication
Relatlimab is indicated in combination with nivolumab, in the combination product Opdualag, for the treatment of adult and pediatric patients ≥12 years old with unresectable or metastatic melanoma.
- Associated Conditions
- Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Dan Zandberg
- Target Recruit Count
- 80
- Registration Number
- NCT04080804
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG
- Conditions
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University Hospital, Essen
- Target Recruit Count
- 21
- Registration Number
- NCT04062656
- Locations
- 🇩🇪
University Hospital Essen, Essen, Germany
🇩🇪Hämatologisch- Onkologische Praxis Eppendorf (HOPE), Hamburg, Germany
🇩🇪Uniklinik Köln, Köln, Germany
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT03978611
- Locations
- 🇺🇸
Local Institution - 0002, Los Angeles, California, United States
🇧🇪Local Institution - 0018, Bruxelles, Brussels, Belgium
🇧🇪Local Institution - 0016, Brussels, Belgium
Pan Tumor Rollover Study
- Conditions
- Interventions
- Drug: NivolumabDrug: LeucovorinDrug: Nivolumab + RelatlimabDrug: RegorafinibDrug: CapecitabineDrug: PemetrexedDrug: EnzalutamideDrug: SunitinibDrug: PembrolizumabDrug: RelatlimabDrug: TemozolomideDrug: RucaparibDrug: IpilimumabDrug: DaratumumabDrug: FluorouracilDrug: CabozantinibDrug: TrametinibDrug: BevacizumabDrug: Oxaliplatin
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1500
- Registration Number
- NCT03899155
- Locations
- 🇧🇷
Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil
🇨🇳Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Local Institution - 0172, Changsha, Hunan, China
Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
- Conditions
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- John Kirkwood
- Target Recruit Count
- 42
- Registration Number
- NCT03743766
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Elizabeth Davis
- Target Recruit Count
- 2
- Registration Number
- NCT03724968
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-05-03
- Target Recruit Count
- 59
- Registration Number
- NCT03642067
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 21
- Registration Number
- NCT03610711
- Locations
- 🇺🇸
Alleghany Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Baylor University, Dallas, Texas, United States
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-10-23
- Target Recruit Count
- 42
- Registration Number
- NCT03607890
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-03-22
- Target Recruit Count
- 57
- Registration Number
- NCT03521830
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.